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ABSTRACT: Covalent labeling of G protein-coupled receptors (GPCRs) by
small molecules is a powerful approach to understand binding modes,
mechanism of action, pharmacology, and even facilitate structure elucidation.
We report the ﬁrst covalent positive allosteric modulator (PAM) for a class C
GPCR, the mGlu2 receptor. Three putatively covalent mGlu2 PAMs were
designed and synthesized. Pharmacological characterization identiﬁed 2 to bind
the receptor covalently. Computational modeling combined with receptor
mutagenesis revealed T7917.29×30 as the likely position of covalent interaction.
We show how this covalent ligand can be used to characterize the PAM binding
mode and that it is a valuable tool compound in studying receptor function and
binding kinetics. Our ﬁndings advance the understanding of the mGlu2 PAM
interaction and suggest that 2 is a valuable probe for further structural and
chemical biology approaches.
■ INTRODUCTION
Over the past years covalent ligands for G protein-coupled
receptors (GPCRs) have re-emerged as valuable tool
compounds to characterize the structure, expression pattern,
and function of these proteins.1 A major obstacle in GPCR
structure elucidation using crystallization is the dynamic
behavior of their seven-transmembrane (7TM) domain,
especially when in the active state.2 Covalent ligands can
stabilize the 7TM domain of the receptor without the
likelihood of dissociation from the binding site. The use of
covalent ligands for structure elucidation has been taken as an
approach to facilitate receptor crystallization, as was shown
recently for the crystal structures of the adenosine A1 and
multiple β2 adrenergic receptors among others.3,4 Beyond
structural considerations, covalent molecules are valuable
pharmacological tools useful for further understanding of
binding modes and other chemical biology and proteomics
applications.
The metabotropic glutamate (mGlu) receptors belong to the
class C GPCRs and are activated by glutamate, the most
abundant neurotransmitter.5 The mGlu receptors are obligatory
dimers and are characterized by their large extracellular Venus
ﬂytrap (VFT) domain (binding endogenous glutamate) which
is connected to the 7TM domain via a cysteine rich domain.6
For mGlu receptors, allosteric modulators that bind in the 7TM
domain are pursued widely for drug discovery as they are
typically more subtype-selective than orthosteric ligands and
only function in the presence of endogenous agonist.7 Positive
allosteric modulation of the mGlu2 receptor has been shown to
be a potential strategy for the treatment of neurological
disorders such as schizophrenia and anxiety.8 Although the
structure of the extracellular domain of the mGlu2 receptor is
known,9 the current understanding of the structure of the 7TM
domain is based on the crystal structures of the mGlu1 and
mGlu5 7TM domains, which were crystallized in an inactive
state with a negative allosteric modulator (NAM) bound in the
allosteric binding pocket.10−12
We have had a long-standing interest in mGlu2 receptor
PAMs leading to characterization of multiple medicinal
chemistry series13,14 that were also studied with site-directed
mutagenesis.15,16 We have further characterized the binding
kinetics and pharmacology of selected leads.17−19 Robust in
vivo pharmacodynamic eﬀects were observed in several animal
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models with some molecules such as 1-butyl-3-chloro-4-(4-
phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813/
ADX71149) advancing to human clinical trials.20−23 Despite
this, further and more rigorous approaches to understand
mGlu2 PAM binding and receptor pharmacology are needed. In
this study we have designed and synthesized three novel
putatively covalent mGlu2 PAMs based on computational
approaches and previous understanding of the PAM binding
mode. These compounds were fully characterized in vitro,
resulting in the identiﬁcation of 4-[[4-[3-(cyclopropylmethyl)-
8-(triﬂuoromethyl)[1,2,4]triazolo[4,3-a]pyridin-7-yl]phenyl]-
carbamoyl]benzenesulfonyl ﬂuoride (2) as a covalently binding
mGlu2 PAM. The binding mode was studied using computa-
tional docking, which identiﬁed several amino acid residues that
potentially formed the covalent interaction. Using site-directed
mutagenesis, T7917.29×30 was conﬁrmed as the residue
responsible for the covalent interaction.
■ RESULTS AND DISCUSSION
Chemistry. On the basis of a series of analogues of 3-
(cyclopropylmethyl)-7-[(4-phenyl-1-piperidinyl)methyl]-8-(tri-
ﬂuoromethyl)-1,2,4-triazolo[4,3-a]pyridine (1 , JNJ-
46281222),24 we recently developed a novel series of mGlu2
PAMs bearing the 7-aryl-1,2,4-triazolo[4,3-a]pyridine as the
core structure.13,17 This scaﬀold was used to design three novel
putative covalent mGlu2 PAMs for which the ﬂuorosulfonyl
moiety was chosen as a reactive warhead. A 4-ﬂuorosulfonyl-
phenyl ring was connected to the 7-phenyl-1,2,4-triazolo[4,3-
a]pyridine-core via an amide linker to the phenyl ring at the 4-
position (2), the 3-position (3), or the 4-position with a
methylene spacer in between to increase ﬂexibility (4), as
depicted in Figure 1. The synthesis of target compounds 2−4 is
shown in Scheme 1. They were prepared via Suzuki coupling of
the 7-chlorotriazolopyridine 525 with the corresponding
commercially available boronic acids (6a−c) and subsequent
amide formation of 7a−c with the commercially available
Figure 1. Structures of 1 and novel mGlu2 PAMs 2−4. The position of the tritium label of [3H]-1 is denoted by ∗.
Scheme 1. Synthesis of Compounds 2−4a
aReagents and conditions: (i) Pd(PPh3)4, NaHCO3, H2O/1,4-dioxane, 150 °C, 10−15 min, microwave, 61−68% for 7a−c. (ii) (a) 8a, HATU,
DIPEA, DMF, rt, 3h, 68−75% for 2 and 3, (b) 8b, 1,4-dioxane, 90 °C, 30 min, 33% for 4.
Table 1. Functional Activity (pEC50), Aﬃnity (pKi), and Kinetic Parameters (kon, koff, RT) for mGlu2 PAMs 1−4
compd pEC50
a pKi
a pKi (3 h pre-incubation)
a kon (M
−1 s−1)a koff (s
−1)a RT (min)a,b
1 7.74 ± 0.03 8.12 ± 0.13 8.12 ± 0.19 (1.2 ± 0.072) × 106 c 0.0013 ± 0.0002c 12 ± 2.3c
2 6.80 ± 0.06 7.21 ± 0.11 8.21 ± 0.14* “(3.2 ± 1.2) × 103” “(3.2 ± 3.1) × 10−13” “(5.2 ± 4.9) × 1010”
3 6.80 ± 0.04 6.95 ± 0.11 6.78 ± 0.09 (2.1 ± 0.77) × 104 0.00091 ± 0.00033 18 ± 6.7
4 7.82 ± 0.06 8.24 ± 0.08 8.38 ± 0.10 (2.2 ± 0.17) × 105 0.00057 ± 0.00016 29 ± 8.3
aValues represent the mean ± SEM of at least three individual experiments, performed in duplicate. bRT (min) = 1/(60 × koff).
cAs described
previously.17 *<0.01, unpaired Student’s t test compared to co-incubation.
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chemoreactive group. This electrophilic ﬂuorosulfonyl moiety
was chosen as a warhead to achieve a covalent interaction with
a nucleophilic amino acid at the allosteric binding pocket of the
mGlu2 receptor. This moiety has been widely used and was
chosen for its wide reactivity to various nucleophilic residues:
serine, threonine, tyrosine, lysine, cysteine, and histidine.26
Biology and Structure−Reactivity Considerations.
First, the potency of the compounds to enhance the eﬀect of
glutamate at its EC20 was determined using a [
35S]GTPγS
assay. Reference PAM 1 showed a high potency (Table 1;
pEC50 = 7.74 ± 0.03). Compounds 2−4 were all able to
increase the response of the EC20 glutamate concentration to a
similar level as 1 and thus behaved as functional mGlu2 PAMs
with potencies of around 100 nM for 2 and 3 (pEC50 values of
6.80 ± 0.06 and 6.80 ± 0.04, respectively). The highest potency
was found for 4, with a pEC50 value of 7.82 ± 0.06.
Subsequently, the apparent aﬃnities of the compounds were
determined in a [3H]JNJ-46281222 displacement assay (Table
1). The pKi value of 8.12 ± 0.19 for 1 was close to its pEC50
value. Also, 2 and 3 had pKi values close to their pEC50 values,
7.21 ± 0.11 and 6.95 ± 0.11, respectively. Compound 4 had the
highest aﬃnity with a pKi value of 8.24 ± 0.08.
The pEC50 and pKi values (7.74 ± 0.03 and 8.12 ± 0.13,
respectively) of 1 were similar to those reported before.18 The
potency and aﬃnity parameters of 2−4 compared favorably
with the well-studied 1, which was one of the most potent
compounds identiﬁed from the same triazolopyridine scaﬀold
and was used as a control throughout the study. Even though
the ﬂuorosulfonyl moiety at the distal tail in 2−4 was more
bulky and hydrophilic than the unsubstituted phenyl of 1 and
the other compounds studied previously,17,24 the aﬃnity and
potency values were only reduced approximately 10-fold for 2
and 3 compared to 1 and not at all for 4. The shift of the 4-
ﬂuorosulfonylphenyl ring from the 4-position in 2 to the 3-
position in 3 did not change the potency and aﬃnity, whereas
the greater ﬂexibility of the methylene spacer in 4 most likely
resulted in its increased potency and aﬃnity compared to 2.
Selectivity of this series of mGlu2 PAMs was good.
Representative 3 showed no activity at mGlu1,3,5,8 (Table S1
in Supporting Information).
Since a covalent interaction would induce insurmountable
binding to the allosteric binding site, we set up a radioligand
displacement assay using a 3 h pre-incubation of CHO-
K1_hmGlu2 membranes with increasing concentrations of the
four PAMs. This pre-incubation was followed by addition of
[3H]JNJ-46281222 and a subsequent incubation for 1 h. Data
were compared to the control experiments with no pre-
incubation, i.e., co-incubation of the radioligand and the
compounds studied.
Compound 1 showed no diﬀerence in aﬃnity between the
co-incubation and the pre-incubation assays (Table 1; pKi =
8.12 in both cases), indicating that 1 does not bind
insurmountably to the allosteric binding pocket. On the
contrary, the addition of a pre-incubation step resulted in a
10-fold increase in aﬃnity for 2 (Table 1; Figure 2A), indicating
that this compound binds the receptor insurmountably as no
re-equilibration of 2 occurred after addition of [3H]JNJ-
46281222. Both 3 and 4 did not reveal a signiﬁcant shift in
receptor aﬃnity when tested in the two-step binding assay,
indicating they do not bind the receptor insurmountably. The
observation of a shift in aﬃnity of 2 after pre-incubation is in
agreement with previously described covalent ligands for the
histamine H4 and adenosine A2A receptors.
27,28
Competition binding experiments are generally not the
preferred method for evaluation of covalent interactions with
GPCRs.29,30 Therefore, the kinetic parameters kon and koff of
Figure 2. (A) Displacement of [3H]JNJ-46281222 by 2 with and without a pre-incubation of 3 h. (B) Competition association assay of 2 at its IC50
concentration determined in the co-incubation assay. (C) [3H]JNJ-46281222 binding after pre-incubation with a 10 × IC50 concentration of mGlu2
PAM followed by four extensive washing cycles. (D) [3H]JNJ-46281222 binding after pre-incubation with increasing concentrations of 2 followed by
four extensive washing cycles. Data represent the mean ± SEM of at least three individual experiments performed in duplicate: (∗) p < 0.01; (∗∗) p
< 0.0001, one-way ANOVA with Dunnett’s post-test compared to control.
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1−4 were determined (Table 1). The kinetic parameters for 1
were determined in classical [3H]JNJ-46281222 association and
dissociation experiments, yielding the association rate constant
kon (k1 = 1.2 × 10
6 M−1 s−1) and dissociation rate constant koff
(k2 = 0.0013 s
−1), leading to a residence time (RT) of 12 min.
Using these values, we determined the kinetic kon (k3) and koff
(k4) values for 2−4 using a competition association assay based
on the Motulsky and Mahan model.31 In contrast to 1, 2
showed a much slower on-rate (3.2 × 103 M−1 s−1) and a
negligible oﬀ-rate (3.2 × 10−13 s−1), leading to an inﬁnite RT,
indicative for irreversible binding. The competition association
curve of 2 shows an overshoot followed by a declining curve
that did not reach equilibrium (Figure 2B). Compound 3
showed an on-rate of 2.1 × 104 M−1 s−1 and an oﬀ-rate of
0.000 91 s−1, leading to a RT of 18 min, which is comparable to
1. The on-rate of 4 was 10-fold faster (2.2 × 105 M−1 s−1) and
oﬀ-rate slower than 3 (0.000 57 s−1), leading to a RT of 29 min.
The values for 3 and 4 indicate reversible binding behavior
which is in line with the displacement experiments. The shape
of the competition association curve of 2 (Figure 2B) is typical
for an irreversible interaction, similar to that seen recently with
the irreversibly binding FSCPX at the adenosine A1 receptor.
32
As the values determined for kon and koff of 2 are far from the
kinetic parameters of the radioligand and beyond the duration
of the experiments, they should be considered approximate
values. Still, this does not change the conclusion of an inﬁnite
RT. Furthermore, 2 can be used as a tool compound for
studying binding kinetics of allosteric modulators at the mGlu2
receptor, a strategy that was followed before for the adenosine
A1 receptor.
33
To distinguish between irreversible and pseudoirreversible
interactions of 2−4, we performed radioligand binding assays
followed by extensive washing steps. A washout assay was
developed in which 1 h pre-incubation with a 10 × IC50
concentration of compound was followed by at least three
extensive wash and centrifugation cycles. After the subsequent
incubation with [3H]JNJ-46281222, radioligand displacement
was assessed and compared to the control condition without
any competitor (100% radioligand binding). For 1 (unlabeled
JNJ-46281222), no radioligand displacement was found,
indicating that 1 was completely washed away (Figure 2C).
For compounds 3 and 4, [3H]JNJ-46281222 was displaced
partially, indicating that a portion of the receptor population
was still bound but no persistent covalent interactions occurred.
This partial recovery of 3 and 4 was likely caused by their
slower binding kinetics compared to 1. Pre-incubation with
compound 2 completely abolished [3H]JNJ-46281222 binding
after the washing cycles, indicating its irreversible binding to the
mGlu2 receptor (Figure 2C). This was further conﬁrmed by
pre-incubation with increasing concentrations of 2, followed by
four extensive washing cycles. For this eﬀect a concentration−
response curve was established, with an apparent pKi value for 2
of 6.63 ± 0.14 which is another qualitative assessment of the
irreversible interaction.
To evaluate the eﬀect of irreversible binding of 2 on the
functional PAM response, the following [35S]GTPγS setup was
used. Increasing concentrations of 2 and a glutamate
concentration equivalent to its EC20 value were preincubated
with membranes for 3 h, followed by a 1 h incubation with
[35S]GTPγS, resulting in a potency of 6.75 ± 0.13, which was 7-
fold higher than when co-incubation only was performed
(pEC50 = 5.90 ± 0.08) (Figure 3A). The pEC50 value
determined after 3 h pre-incubation followed by 1 h co-
incubation with [35S]GTPγS (6.75 ± 0.13) was similar to the
potency assessed in the standard [35S]GTPγS protocol (6.80 ±
0.06), which also included a pre-incubation step.
The ability of bound 2 to behave as a PAM was studied by
repeating the washout assay but with a [35S]GTPγS binding
assay subsequent to the washing cycles (Figure 3B).
Compound 2 was still able to induce [35S]GTPγS binding in
the presence of an EC20 concentration of glutamate after the
washing steps. The level was comparable to the control
situation in which the compound was added after the washing
steps. As a further control, the assay was also performed using
1, which did not induce [35S]GTPγS binding as it was washed
away (Figure 2C), in contrast to the situation in which 1 was
added after washing (Figure 3B).
Computational Modeling. It is well understood that
allosteric modulators of mGlu receptors bind in the 7TM
domain in a similar conserved site as class A GPCRs.7
Crystallography has shown variation in the exact location of
allosteric ligands in this site.34 Our previous experimental and
computational studies have helped to pinpoint the binding
mode of mGlu2 receptor PAMs of several chemical series.
15,16
This work greatly helped the design of molecules 2−4. With a
strong certainty that the triazolopyridine core binds deepest in
the receptor,16,18 we designed and docked multiple diﬀerent
candidate ﬂuorosulfonylphenyl molecules. Idea molecules were
docked into a homology model of the mGlu2 receptor allosteric
binding site using a model and approach as described
Figure 3. (A) Compound-induced [35S]GTPγS binding after 60 min of incubation with [35S]GTPγS with or without a 3 h pre-incubation in the
presence of a glutamate concentration equivalent to its EC20 value. (B) [
35S]GTPγS binding after stimulation with a 10 × IC50 concentration of
mGlu2 PAM which was added either before or after four extensive washing cycles. All experiments were performed in the presence of a glutamate
concentration equivalent to its EC20 value. Data represent the mean ± SEM of at least three individual experiments performed in duplicate: (∗∗) p <
0.0001, unpaired Student’s t test.
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previously.16,24 Due to ﬂexibility and sequence diﬀerences,
there is increased uncertainty of the amino acid position and
conformation in the extracellular side of the receptor model.
From the docking, 2−4 allowed the ﬂuorosulfonyl to explore
diﬀerent vectors and depths of the extracellular side of the
binding site. Our approach relying upon a model of the ligand
receptor binding mode, and not a crystal structure, was more
high risk. Therefore, we chose the ﬂuorosulfonylphenyl as the
warhead because it can react with various nucleophilic amino
acids as to increase the chance to ﬁnd a covalent ligand.
The docking results for molecule 2 showed the triazolopyr-
idine core overlapped with that of 1 (Figure 4), which was
included in earlier reports. As mentioned, this positioning and
orientation of the scaﬀold are consistent with previous SAR and
mutagenesis work.35 The ﬂexible distal tail of 2 containing the
ﬂuorosulfonyl moiety was pointing toward the top of
transmembrane helix 3 or 7 and extracellular loop (ECL) 2.
As suggested by the mGlu1 structure, ECL2 forms a lid on top
of the 7TM pocket in all class C GPCRs, which is likely
happening to mGlu2 as well.
10,36 While the scaﬀold consistently
adopted the shown binding orientation, two diﬀerent binding
modes were possible for the distal part of the molecule (Figure
4). In the ﬁrst binding mode, the distal phenyl relaxes into the
7TM of the receptor. This is analogous to the binding mode
and behavior of 1 reported in previous computational studies,18
as shown comparing pale blue and dark orange molecules in
Figure 4. The ﬂuorosulfonyl moiety is presented close to
T7917.29×30 located in our model at the top of TM-7. If the
ligand maintains a more linear orientation, it will present a
second possible binding mode as shown in pale orange in
Figure 4, where the ﬂuorosulfonyl group points toward two
alternative arginines: R6353.32×32 and R720 (ECL2).
Receptor Mutagenesis. On the basis of the two potential
binding modes of 2, multiple nucleophilic amino acid residues
were within a radius of 4 Å to the ﬂuorosulfonyl warhead and
hence were potential candidates to form the covalent bond with
the ﬂuorosulfonyl. Although arginines are not widely reported
to behave as nucleophiles, the proximity of several in the
extracellular region may permit some to be less protonated, and
we therefore did not want to overlook this possibility. The
amino acids included R6353.32×32 and R720 (ECL2) and
T7917.29×30. Meanwhile, Y787 (ECL3) and C7957.33×34 were
further away, but given the ﬂexibility of the extracellular region
of the receptor, they were still considered as possible candidates
for interaction with the ligand warhead.
For all these ﬁve residues alanine substitutions were made.
These mGlu2 receptor mutants were transiently transfected into
CHO-K1 cells, and membrane preparations were made.
Control experiments conﬁrmed the integrity and function of
the mutant receptors, as shown in the Supporting Information
(Figure S1, Table S2). [3H]LY341495 binding experiments
were performed to assess the expression of transiently
transfected WT and mutant mGlu2 receptors, revealing a
similar aﬃnity of glutamate for the WT and all mutants, which
conﬁrmed the integrity of the orthosteric binding pocket. All
mutants were still able to induce [35S]GTPγS binding upon
stimulation by glutamate with similar potencies, which
conﬁrmed the function of the receptor was maintained.
Furthermore, all mutants were still able to bind [3H]JNJ-
46281222, which was displaced by unlabeled 1 with similar
aﬃnities, which conﬁrmed the integrity of the allosteric binding
site (Figure S1, Table S2).
To evaluate which of the amino acid residues was responsible
for covalent binding of 2, the washout assay was repeated
(Figure 5A). Compound 1 was used as a control and showed
around maximal [3H]JNJ-46281222 binding after washing in all
cases, conﬁrming that 1 was washed away during the washing
cycles. The transiently transfected WT mGlu2 showed a similar
eﬀect of 2 after washing compared to the stable CHO-
K1_hmGlu2 cell line, i.e., complete inhibition of [
3H]JNJ-
46281222 binding. Mutants R6353.32×32A, R720A, Y787A, and
C7957.33×34A showed a similar negligible level of [3H]JNJ-
46281222 binding, indicating that 2 was still binding covalently.
However, T7917.29×30A showed [3H]JNJ-46281222 binding to
all available binding sites and thus a loss of covalent binding.
A full curve [3H]JNJ-46281222 displacement assay using the
T7917.29×30A mutant revealed a pKi for 2 of 6.45 ± 0.03 (Figure
5C), which was similar to the transiently transfected WT mGlu2
receptor (Figure 5B; 6.76 ± 0.04) but lower than the pKi found
at the CHO-K1_hmGlu2 membranes (Table 1). This
discrepancy is likely caused by the diﬀerence in technique
used, a ﬁltration binding assay in contrast to an SPA assay.
The loss of irreversible interaction for the T7917.29×30A
mutant was further conﬁrmed in the displacement assay, as the
[3H]JNJ-46281222 displacement curves of 2 with and without
pre-incubation step lost the large shift shown on the WT
receptor (Figure 5C) and were almost overlapping for this
mutant (Figure 5B), indicating a loss of insurmountable
binding behavior. Together, these experiments indicated that
T7917.29×30 was the residue responsible for making the covalent
bond between the receptor and 2. A similar approach was used
recently for the adenosine A2A and neurotensin NTS1 receptors
where a lysine and cysteine residue were found to be
responsible for the covalent interaction, respectively.28,37 The
position of the covalent bond was used to predict the binding
mode of 2, which further increased the understanding of the
Figure 4. Proposed binding mode of mGlu2 PAMs 1 (pale blue) and 2
(dark and pale orange). The two possible binding modes for 2 are
distinguished using dark and pale orange coloring. The ﬁve amino
acids chosen as possible candidates for the covalent interaction are
highlighted in salmon color and labeled.
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binding of PAMs to the binding pocket in addition to our
recent mutagenesis and computational work.15,16,18
Compound 2 can be a useful structural biology tool as it
would be expected to stabilize the 7TM domain in its active
state, thereby potentially facilitating crystallization of the active
state receptor. This could be highly valuable for structure
elucidation of an active state of a class C GPCR which up to
now remains unreported. Furthermore, there is no crystal
structure of the 7TM domain of the mGlu2 receptor. Thus far,
the crystal structures of class C 7TM domains were the NAM
bound structures of mGlu1 and mGlu5.
10−12 A PAM bound
structure would greatly enhance our understanding of the
activation mechanism of class C GPCRs. Recently Gregory et
al. (2016) published the ﬁrst clickable covalent photoaﬃnity
ligands for the mGlu5 receptor.
38 These ligands are NAMs for
the receptor and bind the receptor covalently upon photo-
activation. The ligands contain an alkyne click handle that can
be used for conjugation of clickable dyes. These probes can
then be used for various purposes such as imaging in native
tissues.38 Such a strategy is also of interest for the mGlu2
receptor, and 2 may be used as a starting point for further
chemical optimization.
Covalent ligands have proved to be successful medicines for
various indications, but due to safety concerns, they are mostly
neglected in drug discovery.39 This is especially the case for
neuroscience indications that often require chronic treatment,
thus exacerbating such fears. Nevertheless, the introduction of
covalent warheads into ligands that were optimized for
noncovalent aﬃnity may overcome some of the expected
diﬃculties of oﬀ-target-activities. Such highly targeted, selective
covalent inhibitors represent the current state of the art.40
Furthermore, covalent allosteric modulators are even more
likely to be used as therapeutics compared to orthosteric
ligands since they lack intrinsic eﬃcacy, thereby avoiding
problems due to on-target toxicity.41
■ CONCLUSION
This study reports the design, synthesis, and pharmacological
characterization of the ﬁrst covalent PAM for a class C GPCR.
In addition, a combined computational and mutagenesis
approach enabled the identiﬁcation of T7917.29×30 as the
position of the covalent interaction. Due to its favorable
allosteric properties, this compound may be considered a tool
compound to further evaluate the use of covalent ligands as
potential GPCR therapeutics. Furthermore, it enhances the
understanding of the binding mode of PAMs, may be
considered a starting point of further development of a
functionalized PAM probe, and could be a valuable tool
compound for structure elucidation of the mGlu2 receptor.
■ EXPERIMENTAL SECTION
Chemistry. Unless otherwise noted, all reagents and solvents were
obtained from commercial suppliers and used without further
puriﬁcation. Thin layer chromatography (TLC) was carried out on
silica gel 60 F254 plates (Merck). Flash column chromatography was
performed on silica gel, particle size 60 Å, mesh = 230−400 (Merck),
under standard techniques. Microwave assisted reactions were
performed in a single-mode reactor, Biotage Initiator Sixty microwave
reactor (Biotage), or in a multimode reactor, MicroSYNTH Labstation
(Milestone, Inc.). Nuclear magnetic resonance (NMR) spectra were
recorded with either a Bruker DPX-400 or a Bruker AV-500
spectrometer (Bruker AG) with standard pulse sequences NMR data
operating at 400 and 500 MHz, respectively, using CDCl3 and DMSO-
d6 as solvents. Chemical shifts (δ) are reported in parts per million
(ppm) downﬁeld from tetramethylsilane (δ = 0). Coupling constants
Figure 5. (A) [3H]JNJ-46281222 binding to transiently transfected mGlu2 mutants after pre-incubation with 1 or 2 at a 10 × IC50 concentration
followed by four extensive washing cycles. (B) C.) Displacement of speciﬁc [3H]JNJ-46281222 binding from transiently transfected WT (B) and
T7917.29×30A (C) mGlu2 receptor by 2 with and without a pre-incubation of 3 h. Experiments were performed in the presence of a glutamate
concentration equivalent to its EC20 value. Data represent the mean ± SEM of at least three individual experiments performed in duplicate: (∗∗) p <
0.0001, one-way ANOVA with Dunnett’s post-test compared to WT.
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are reported in hertz. Splitting patterns are deﬁned by s (singlet), d
(doublet), dd (double doublet), t (triplet), q (quartet), quin (quintet),
sex (sextet), sep (septet), or m (multiplet). Liquid chromatography
combined with mass spectrometry (LC−MS) was performed on either
a HP 1100 HPLC system (Agilent Technologies) or Advanced
Chromatography Technologies system composed of a quaternary or
binary pump with degasser, an autosampler, a column oven, a diode
array detector (DAD), and a column as speciﬁed in the respective
methods. Flow from the column was split to a MS spectrometer. The
MS detector was conﬁgured with either an electrospray ionization
source or an ES-CI dual ionization source (electrospray combined with
atmospheric pressure chemical ionization). Nitrogen was used as the
nebulizer gas. Data acquisition was performed with MassLynx-
Openlynx software or with Chemstation-Agilent Data Browser
software.
Compounds are described by their experimental retention times
(tR) and ions. The reported molecular ion corresponds to the [M +
H]+ (protonated molecule) and/or [M − H]− (deprotonated
molecule). Purities of all new compounds were determined by
analytical RP-HPLC using the area percentage method on the UV
trace recorded at a wavelength of 254 nm, and compounds were found
to have ≥95% purity unless otherwise speciﬁed. More detailed
information about the diﬀerent LC−MS methods employed can be
found in the Supporting Information.
4-[[4-[3-(Cyclopropylmethyl)-8-(triﬂuoromethyl)[1,2,4]-
triazolo[4,3-a]pyridin-7-yl]phenyl]carbamoyl]benzenesulfonyl
Fluoride (2). DIPEA (0.079 mL, 0.4514 mmol) was added to a stirred
solution of 7a (0.1 g, 0.301 mmol), 8a (0.074 mg, 0.3611 mmol), and
HATU (0.195 mg, 0.512 mmol) in DMF (2 mL). The mixture was
stirred at room temperature for 3 h. The mixture was diluted with
CH2Cl2 and washed with sat. NH4Cl and NaHCO3 aqueous saturated
solution. The organic layer was separated, dried (Na2SO4), ﬁltered,
and the solvents were evaporated in vacuo. The crude product was
puriﬁed by ﬂash column chromatography (silica; CH2Cl2 in MeOH
100/0 to 94/6). The desired fractions were collected and the solvents
evaporated in vacuo to yield 2 (0.116 g, 75%). 1H NMR (500 MHz,
DMSO-d6) δ 10.84 (s, 1H), 8.75 (d, J = 7.22 Hz, 1H), 8.22−8.41 (m,
4H), 7.93 (d, J = 8.38 Hz, 2H), 7.47 (d, J = 8.67 Hz, 2H), 6.97 (d, J =
6.94 Hz, 1H), 3.15 (d, J = 6.94 Hz, 2H), 1.19−1.31 (m, 1H), 0.46−
0.66 (m, 2H), 0.23−0.41 (m, 2H). LC−MS: m/z 519 [M + H]+, tR =
2.24 min.
4-[[3-[3-(Cyclopropylmethyl)-8-(triﬂuoromethyl)[1,2,4]-
triazolo[4,3-a]pyridin-7-yl]phenyl]carbamoyl]benzenesulfonyl
Fluoride (3). Starting from 7b (0.260 g, 0.7824 mmol) and 8b (0.192
mg, 0.9388 mmol) and following the procedure described for 2,
compound 3 was obtained (0.274 g, 68%). 1H NMR (500 MHz,
DMSO-d6) δ 10.83 (s, 1H), 8.76 (d, J = 7.22 Hz, 1H), 8.22−8.42 (m,
4H), 7.81−7.99 (m, 2H), 7.54 (t, J = 7.80 Hz, 1H), 7.21 (d, J = 7.80
Hz, 1H), 6.96 (d, J = 7.22 Hz, 1H), 3.15 (d, J = 6.65 Hz, 2H), 1.12−
1.37 (m, 1H), 0.46−0.66 (m, 2H), 0.23−0.42 (m, 2H). LC−MS: m/z
519 [M + H]+, tR = 2.24 min.
4-[[4-[3-(Cyclopropylmethyl)-8-(triﬂuoromethyl)[1,2,4]-
triazolo[4,3-a]pyridin-7-yl]phenyl]methylcarbamoyl]benzene-
sulfonyl Fluoride (4). 7c (0.050g, 0.144 mmol) in 1,4-dioxane (0.5
mL) was added to 8b (0.038 g, 0.173 mmol). The resulting suspension
was heated at 90 °C for 30 min. After cooling, the suspension was
ﬁltered, washed with Et2O, and dried under vacuum. The crude
product was puriﬁed by ﬂash column chromatography (silica; CH2Cl2
in MeOH 100/0 to 94/6) to give 4 as a white solid (0.025 g, 33%). 1H
NMR (400 MHz, DMSO-d6) δ 9.55 (t, J = 5.90 Hz, 1H), 8.73 (d, J =
6.94 Hz, 1H), 8.13−8.39 (m, 4H), 7.31−7.55 (m, 1H), 6.92 (d, J =
7.40 Hz, 1H), 4.62 (d, J = 6.01 Hz, 2H), 3.13 (d, J = 6.70 Hz, 2H),
1.14−1.31 (m, 2H), 0.45−0.62 (m, 2H), 0.20−0.40 (m, 2H). LC−MS:
m/z 533 [M + H]+, tR = 2.13 min.
4-[3-(Cyclopropylmethyl)-8-(triﬂuoromethyl)[1,2,4]triazolo-
[4,3-a]pyridin-7-yl]aniline (7a). Pd(PPh3)4 (0.075 g, 0.065 mmol)
was added to a stirred suspension of 5 (0.300 g, 1.0883 mmol) and 6a
(0.164 g, 1.197 mmol) in a saturated aqueous solution of NaHCO3 (2
mL) and 1,4-dioxane (5 mL). The mixture was heated at 150 °C for 15
min under microwave irradiation, then cooled to room temperature
and ﬁltered through a Celite pad. The ﬁltrate was diluted with water
(20 mL) and extracted with EtOAc (2 × 15 mL). The organic layer
was washed with brine (15 mL), dried over anhydrous Na2SO4, and
concentrated in vacuo. The crude was puriﬁed by ﬂash column
chromatography (silica gel, MeOH−NH3 in CH2Cl2, 0/100 to 5/95)
to give the desired product 7a as a pale yellow solid (0.227 g, 61%).
LC−MS: m/z 333 [M + H]+, tR = 1.62 min.
3-[3-(Cyclopropylmethyl)-8-(triﬂuoromethyl)[1,2,4]triazolo-
[4,3-a]pyridin-7-yl]aniline (7b). Starting from 5 (0.300 g, 1.0883
mmol) and 6b (0.208 g, 1.197 mmol) and following the procedure
described for 7a, compound 7b was obtained as a pale yellow solid
(0.265 g, 68%). LC−MS: m/z 333 [M + H]+, tR = 1.64 min.
[4-[3-(Cyclopropylmethyl)-8-(triﬂuoromethyl)[1,2,4]triazolo-
[4,3-a]pyridin-7-yl]phenyl]methanamine (7c). Starting from 5
(0.300 g, 1.0883 mmol) and 6c (0.279 g, 1.197 mmol) and following
the procedure described for 7a, compound 7c was obtained as a pale
yellow solid (0.245 g, 65%). LC−MS: m/z 347 [M + H]+, tR = 1.5
min.
Biology. Cell Culture. CHO-K1 cells (CCL-61; ATCC, Rockville,
MD, USA) were grown in Dulbecco’s modiﬁed Eagle’s medium/
nutrient F-12 Ham (DMEM/F12) supplemented with 10% (v/v) fetal
calf serum, 100 IU·mL−1 penicillin, 100 μg·mL−1 streptomycin, and
100 mM pyruvate. CHO-K1 cells stably expressing the wild-type
(WT) hmGlu2 receptor (CHO-K1_hmGlu2; Janssen Research and
Development) were grown in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% (v/v) fetal calf serum, 200 IU·mL−1
penicillin, 200 μg·mL−1 streptomycin, 30.5 μg·mL−1 L-proline, and 400
μg·mL−1 G418. All cells were grown at 37 °C and 5% CO2 and were
subcultured at a ratio of 1:10 twice every week.
Plasmids and Transient Transfection. cDNA encoding human
mutated and nonmutated mGlu2 receptors were synthesized by
GeneArt (Life Technologies, Carlsbad, CA, USA), subcloned to the
pcDNA3.1(+) expression vector (Life Technologies) and ampliﬁed by
E. coli transformation. At 24 hours before transfection, cells were
seeded in 15 cm ⌀ culture plates at high density (20 000 cells/cm2).
Transient transfections in CHO-K1 cells were performed using the
cationic lipid transfection reagent LTX Lipofectamine reagent (Life
Technologies).
Cell Membrane Preparation. CHO-K1_hmGlu2 cells in DMEM
without G418 were plated into 15 cm ⌀ plates. Upon growth to 70%
conﬂuency sodium butyrate (ﬁnal concentration 5 mM) was added to
the plates.42 After 24 h, cells were detached by scraping into 5 mL of
PBS and subsequently centrifuged at 1500 rpm for 5 min. Pellets were
resuspended in ice-cold Tris buﬀer (50 mM Tris-HCl, pH 7.4) and
homogenized using an Ultra Turrax homogenizer at 24 000 rpm (IKA-
Werke GmbH & Co.KG, Staufen, Germany). Membranes and the
cytosolic fraction were separated by centrifugation at 31 000 rpm at 4
°C for 20 min in an Optima LE-80 K ultracentrifuge (Beckman
Coulter, Fullerton, CA). After resuspension of pellets in 10 mL of Tris
buﬀer, the centrifugation and homogenization steps were repeated.
The remaining pellets were suspended into assay buﬀer (50 mM Tris-
HCl, pH 7.4, 2 mM CaCl2, 10 mM MgCl2) which was followed by
homogenization. Aliquots were stored at −80 °C.
[3H]JNJ-46281222 Binding Assays Using CHO-K1_hmGlu2
Membranes. Membrane homogenates (15 μg) and prewetted
wheat-germ agglutinin coated SPA beads (0.2 mg; RPNQ0001,
PerkinElmer, Groningen, The Netherlands) were precoupled in assay
buﬀer while gently shaking at room temperature for 30 min. Then, this
membrane bead mixture was added to an Isoplate-96 (PerkinElmer)
together with 6 nM [3H]JNJ-46281222 and increasing concentrations
of competing ligand. Nonspeciﬁc binding was determined using 10 μM
JNJ-40068782 (9).43 In the case of pre-incubation experiments,
[3H]JNJ-46281222 was added after a 3 h pre-incubation of the samples
containing membrane and competitor. Plates were counted in a
Microbeta 24502 Trilux scintillation microplate counter (PerkinElmer)
after a 1 h incubation at 25 °C.
For competition association experiments, the plate was rapidly
placed in the microplate counter after addition of the membrane
homogenates. Plates were recorded for 120 min measuring every 30 s
at ambient temperature. The assay buﬀer in these experiments
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contained 1 mM glutamate, as this was shown to induce monophasic
association and dissociation. This enabled straightforward determi-
nation of kinetic parameters and resembles a condition at which PAMs
likely exert their eﬀect under physiological conditions.18
[3H]JNJ-46281222 Binding Assays Using Transiently Trans-
fected CHO-K1 hmGlu2 Membranes. Membrane homogenates (30
or 60 μg) were diluted in ice-cold assay buﬀer (50 mM Tris-HCl, pH
7.4, 2 mM CaCl2, 10 mM MgCl2) to a total reaction volume of 100 μL
containing increasing concentrations of competing ligand and 6 nM
[3H]JNJ-46281222. Nonspeciﬁc binding was determined using 10 μM
9. After 1 h at 15 °C, incubation was terminated by rapid ﬁltration over
GF/C ﬁlters through a Brandel harvester 24 (Brandel, Gaithersburg,
MD, USA). Filters were subsequently washed at least three times using
ice-cold wash buﬀer (50 mM Tris-HCl, pH 7.4). Filter-bound
radioactivity was determined using liquid scintillation spectrometry
on a TRI-Carb 2810 TR counter (PerkinElmer).
Irreversible Binding of [3H]JNJ-46281222 to CHO-
K1_hmGlu2 and Transiently Transfected hmGlu2 Membranes.
Membrane homogenates (30, 60, or 120 μg) were chosen such that
speciﬁc binding was close to 10% to allow for good resolution and
avoid ligand depletion. Samples were incubated with mGlu2 PAMs 1−
4 at a 10 × IC50 concentration in a total volume of 400 μL (CHO-
K1_hmGlu2 membranes) assay buﬀer containing 1 mM glutamate in
Eppendorf tubes. 0.25% DMSO was taken as a control for total
binding and nonspeciﬁc binding.
After incubation for 1 h at 25 °C while gently shaking, the samples
were centrifuged at 16 100g at 4 °C for 5 min. Unbound ligands were
removed by aspiration of supernatant. An amount of 1 mL of assay
buﬀer was added, pellets were resuspended, and samples were
incubated for 20 min at 25 °C. This centrifugation and washing
cycle was repeated 4 times. After that, supernatant was removed and
the membranes were resuspended in a total volume of 400 μL (CHO-
K1_hmGlu2) or 100 μL (transiently transfected hmGlu2 mutants)
containing 6 nM [3H]JNJ-46281222 and 1 mM glutamate in tubes.
Nonspeciﬁc binding was determined using 10 μM 9. After 1 h
incubation at 25 °C, incubations were terminated and samples
obtained and analyzed as described under “[3H]JNJ-46281222
Binding” sections.
[35S]GTPγS Binding Assays. Membrane homogenates (5 or 10
μg) were diluted in ice-cold assay buﬀer (50 mM Tris-HCl, pH 7.4,
100 mM NaCl, 3 mM MgCl2) supplemented with 10 μM GDP
(Sigma-Aldrich, St. Louis, MO, USA) and 5 μg of saponin to a total
reaction volume of 80 μL containing increasing concentrations of
ligand of interest and a glutamate concentration equivalent to its EC20
value (4 μM) in the case of a PAM dose−response curve. Basal
receptor stimulation was determined using assay buﬀer, and maximum
receptor stimulation was determined using 1 mM glutamate. Samples
were preincubated for 30 min at 25 °C. Subsequently, 20 μL of
[35S]GTPγS (ﬁnal concentration 0.3 nM; PerkinElmer) was added.
The reaction was stopped after a 90 min incubation at 25 °C by rapid
ﬁltration through a 96-well GF/B ﬁlterplate (PerkinElmer) on a
PerkinElmer FilterMate harvester. Plates were washed with ice-cold
wash buﬀer (50 mM Tris-HCl, pH 7.4, 5 mM MgCl2). Filter-bound
radioactivity was determined by scintillation spectrometry using the
Microbeta2 counter.
Irreversible Binding to CHO-K1_hmGlu2 Membranes in a
Functional [35S]GTPγS Binding Assay. Experiments were per-
formed as described under “Irreversible Binding of [3H]JNJ-46281222
to CHO-K1_hmGlu2 and Transiently Transfected hmGlu2 Mem-
branes”, with assay buﬀer as described under “[35S]GTPγS Binding
Assays”. PAMs were diluted in assay buﬀer containing a glutamate
concentration equivalent to its EC20 value (4 μM). After the washing
steps, membrane suspensions were transferred to tubes in a volume of
360 μL of assay buﬀer containing saponin (10 μg) and GDP (10 μM).
PAM samples contained an EC20 glutamate concentration, total
binding was determined using 1 mM glutamate, and basal [35S]GTPγS
binding was determined using assay buﬀer only. Samples were
preincubated for 30 min at 25 °C. Subsequently, 40 μL of [35S]GTPγS
(ﬁnal concentration 0.3 nM) was added. The reaction was stopped
after a 30 min incubation at 25 °C by rapid ﬁltration over GF/B ﬁlters
through a Brandel harvester 24 (Brandel, Gaithersburg, MD, USA).
Filters were subsequently washed at least three times using ice-cold
wash buﬀer (50 mM Tris-HCl, pH 7.4, 5 mM MgCl2). Samples were
analyzed as described under “[3H]JNJ-46281222 Binding” sections.
[3H]LY341495 Binding Assays. Membrane homogenates (5 μg)
were diluted in assay buﬀer (50 mM Tris-HCl, pH 7.4, 2 mM CaCl2,
10 mM MgCl2) to a total reaction volume of 100 μL containing
increasing concentrations of glutamate (100 nM to 1 mM) and 3 nM
[3H]LY341495 (ARC, St. Louis, MO, USA). Nonspeciﬁc binding was
determined using 1 mM glutamate. After incubation for 1 h at 25 °C,
samples were rapidly ﬁltered through a 96-well GF/B ﬁlterplate
(PerkinElmer) on a PerkinElmer ﬁltermate harvester and washed three
times with ice-cold wash buﬀer (50 mM Tris-HCl, pH 7.4). Samples
were analyzed as described under “[3H]JNJ-46281222 Binding”
sections.
For all radioligand binding experiments DMSO concentrations were
≤0.25% and radioligand concentrations were chosen such that <10%
of the amount added was receptor-bound to avoid ligand depletion.
Data Analysis. Data analyses were performed using Prism 7.00
(GraphPad software, San Diego, CA, USA). pIC50 values were
obtained using nonlinear regression curve ﬁtting into a sigmoidal
concentration−response curve using the equation Y = Bottom + (Top
− Bottom)/(1 + 10(X−log IC50)). pKi values were obtained from pIC50
values using the Cheng−Prusoﬀ equation.44 pEC50 values were
determined using nonlinear regression curve ﬁtting into a sigmoidal
concentration−response curve with variable slope using the equation Y
= Bottom + (Top − Bottom)/(1 + 10((log EC50−X)·Hill slope)). Association
and dissociation rate constants for unlabeled mGlu2 PAMs were
determined by nonlinear regression analysis of competition association
data as described by Motulsky and Mahan.31 In these equations k1 and
k2 represent the kon and koff of [
3H]JNJ-46281222, which are described
in Table 1.
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Data shown represent the mean ± SEM of at least three individual
experiments performed in duplicate. Statistical analysis was performed
if indicated, using a one-way ANOVA with Dunnett’s post-test or an
unpaired Student’s t test. Observed diﬀerences were considered
statistically signiﬁcant if p-values were below 0.05.
Computational Eﬀorts. mGlu2 Receptor Homology Model.
Method is as described before.18 An active state model of the 7TM
domain of human mGlu2 receptor (Uniprot code Q14416) bound to
G protein was built using a combination of structural templates. The
crystal structure of the human mGlu5 (PDB code 4OO9,
11) was used
to model all 7TM helices except TM6. ECL2 is not reﬁned in the
mGlu5 X-ray structure; therefore this important loop was modeled
based on the mGlu1 receptor crystal structure (PDB code 4OR2,
10).
Finally, the β2AR (PDB code 3SN6,
45) active structure was used to
model both TM6 in its distinct open conformation and the
corresponding G protein. The sequence identity between mGlu2 and
mGlu5 7TMs is 51%. The initial model was constructed in MOE
version 2014.9 (Chemical Computing Group Inc., Montreal, QC,
Canada), and then Maestro (Schrodinger LLC, New York, NY, USA)
was used for structure preparation. The Protein Preparation tool was
used to ﬁx any missing side chains/atoms, PROPKA assigned
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protonation states, the hydrogen bonding network was optimized, and
brief minimization was done until no further change of RMSD to
within 0.5 Å removed any structural clashes.
Docking of 2. The ligand was prepared for docking using Maestro.
Conformational sampling was performed with ConfGen, and multiple
conformers were docked into the mGlu2 active state model using Glide
XP. As there is no ligand in the mGlu2 model, the docking grid was
centered on the ligand position in the mGlu1 receptor structure, based
on superposition of mGlu1 and mGlu2. Sampling was increased in the
Glide docking by turning on expanded sampling and passing 100 initial
poses to postdocking minimization. All other docking parameters were
set to the defaults.
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M. L.; Andreś, J. I.; Alcazar, J.; Alonso, J. M.; Macdonald, G. J.;
Oehlrich, D.; Lavreysen, H.; Ahnaou, A.; Drinkenburg, W.; Mackie, C.;
Pype, S.; Gallacher, D.; Trabanco, A. A. Discovery of 1-Butyl-3-
Chloro-4-(4-Phenyl-1-Piperidinyl)-(1H)-Pyridone (JNJ-40411813): A
Novel Positive Allosteric Modulator of the Metabotropic Glutamate 2
Receptor. J. Med. Chem. 2014, 57, 6495−6512.
(24) Cid, J. M.; Tresadern, G.; Vega, J. A.; De Lucas, A. I.; Del Cerro,
A.; Matesanz, E.; Linares, M. L.; García, A.; Iturrino, L.; Peŕez-Benito,
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